Cortellis

Record new drug approvals: ‘fleeting success’ or here to stay?

With a record 59 new drugs approved by the FDA and 42 new active substances recommended for authorization by the European Medicines Agency, 2018 was a profoundly productive year for biopharma. In a new analysis, Jamie Munro and Helen Dowden from Clarivate Analytics examine whether 2018 represents “a fleeting success” or if there are underlying […]

Potential blockbusters make a splash on market entry

Potential blockbusters make a splash on market entry Earlier this year, the Cortellis Drugs to Watch 2019 report highlighted seven drugs predicted to launch in 2019 and achieve blockbuster status by 2023. By the mid-point of the year, Zolgensma has entered the market as the most expensive drug ever launched, Skyrizi has been approved and […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends,” was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

Drug development challenge: Managing CMC submissions

In the era of Breakthrough Therapy and Fast Track drug designations, chemistry, manufacturing and controls (CMC) submissions can cause delays to bring a drug to market, said Drew Barlow, vice president, regulatory affairs at Syner-G Pharma Consulting.  Companies need to provide enough information to satisfy the regulatory requirements while recognizing that providing too much information early will […]

Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019

Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023, according to Cortellis Drugs to Watch 2019, from Clarivate Analytics. Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan […]

Life sciences innovation: What is it? How do we track it? How do we get more?

Most people working in biopharmaceutical R&D would agree that innovation is important. But, what is innovation? Googling “What is innovation?” returns more than a billion hits. Focusing on the top search result from the Google dictionary doesn’t add further insight: “the action or process of innovating.” However, in producing The Life Sciences Innovation Report: A […]

Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
close